These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2066185)

  • 101. Altered MHC class I antigens in tumors.
    Algarra I; Collado A; Garrido F
    Int J Clin Lab Res; 1997; 27(2):95-102. PubMed ID: 9266279
    [TBL] [Abstract][Full Text] [Related]  

  • 102. On the presence within tumours of clones that differ in sensitivity to cytostatic drugs.
    Håkansson L; Tropé C
    Acta Pathol Microbiol Scand A; 1974 Jan; 82(1):35-40. PubMed ID: 4827349
    [No Abstract]   [Full Text] [Related]  

  • 103. In adequate tumor surgery of chemically induced soft tissue sarcomas--an experimental approach for induction of metastasis formation?
    Katenkamp D; Kosmehl H; Langbein L
    Exp Pathol; 1988; 34(4):209-15. PubMed ID: 3234510
    [TBL] [Abstract][Full Text] [Related]  

  • 104. In vivo inhibition of antitumor immunity by embryonic antigens.
    Lembo R; Parmiani G
    Tumori; 1976; 62(2):211-8. PubMed ID: 1006811
    [No Abstract]   [Full Text] [Related]  

  • 105. Incidence, growth and antigenicity of fibrosarcomas induced by Teflon disc in mice.
    Ménard S; Porta GD
    Tumori; 1976; 62(5):565-73. PubMed ID: 828334
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Further studies on the antigen composition of a mouse sarcoma.
    Krüger G
    Z Krebsforsch; 1969; 73(2):164-71. PubMed ID: 4191607
    [No Abstract]   [Full Text] [Related]  

  • 107. Immune selection in murine tumors. A study of MCA induced sarcomas in normal and immunodeficient mice.
    Engel AM; Svane IM; Rygaard J; Werdelin O
    Folia Microbiol (Praha); 1998; 43(5):483-6. PubMed ID: 9821304
    [No Abstract]   [Full Text] [Related]  

  • 108. Non-H-2-linked genetic control of resistance to BALB/c fibrosarcoma Meth-A.
    Mizushima Y; Sendo F; Takeichi N; Kobayashi H
    J Immunogenet; 1980 Dec; 7(6):447-53. PubMed ID: 7240765
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Structural variations in the H-2 genes of AKR lymphomas.
    Hui K; Minamide L; Prandoni N; Festenstein H; Grosveld FG
    J Immunogenet; 1986; 13(2-3):117-21. PubMed ID: 3819448
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Spontaneous and induced tumors in the guinea pig, with special reference to the factor of age.
    Blumenthal HT; Rogers JB
    Prog Exp Tumor Res; 1967; 9():261-85. PubMed ID: 4863162
    [No Abstract]   [Full Text] [Related]  

  • 111. In vitro growth characteristics associated with benign and metastatic variants of tumor cells.
    Cifone MA
    Cancer Metastasis Rev; 1982; 1(4):335-47. PubMed ID: 6764379
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Failure of Shier's chemical vaccine to protect BALB-c mice against transplant and chemically induced tumors.
    Cook MM; Wagner AF; Larson VM; Tytell AA; Shen TY; Hilleman MR
    Proc Soc Exp Biol Med; 1974 Feb; 145(2):636-40. PubMed ID: 4814156
    [No Abstract]   [Full Text] [Related]  

  • 113. Implication of Amyloid Precursor-like Protein 2 Expression in Cutaneous Squamous Cell Carcinoma Pathogenesis.
    Huang X; Yang J; Xi H; Zhang M; Oh Y; Jin Z; Zheng Z
    In Vivo; 2024; 38(1):399-408. PubMed ID: 38148084
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Cancer immune escape: MHC expression in primary tumours versus metastases.
    Garrido F; Aptsiauri N
    Immunology; 2019 Dec; 158(4):255-266. PubMed ID: 31509607
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations.
    Aptsiauri N; Carretero R; Garcia-Lora A; Real LM; Cabrera T; Garrido F
    Cancer Immunol Immunother; 2008 Nov; 57(11):1727-33. PubMed ID: 18491093
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Gene transfer preferentially selects MHC class I positive tumour cells and enhances tumour immunogenicity.
    Hacker UT; Schildhauer I; Barroso MC; Kofler DM; Gerner FM; Mysliwietz J; Buening H; Hallek M; King SB
    Cancer Immunol Immunother; 2006 May; 55(5):547-57. PubMed ID: 16044254
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours.
    Algarra I; González A; Pérez M; Gaforio JJ; Garrido F
    Clin Exp Immunol; 1996 Mar; 103(3):499-505. PubMed ID: 8608652
    [TBL] [Abstract][Full Text] [Related]  

  • 118. In vivo activation of NK cells induces inhibition of lung colonization of H-2 positive and H-2 negative fibrosarcoma tumor clones.
    Algarra I; Pérez M; Gaforio JJ; Gasca F; Garrido F
    Clin Exp Metastasis; 1994 Jan; 12(1):31-6. PubMed ID: 8287618
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours.
    Cromme FV; van Bommel PF; Walboomers JM; Gallee MP; Stern PL; Kenemans P; Helmerhorst TJ; Stukart MJ; Meijer CJ
    Br J Cancer; 1994 Jun; 69(6):1176-81. PubMed ID: 8198988
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Heterogeneity of MHC-class-I antigens in clones of methylcholanthrene-induced tumors. Implications for local growth and metastasis.
    Algarra I; Gaforio JJ; Garrido A; Mialdea MJ; Pérez M; Garrido F
    Int J Cancer Suppl; 1991; 6():73-81. PubMed ID: 2066185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.